FCCC LOGO Faculty Publications
Benson AB , Venook AP , Bekaii-Saab T , Chan E , Chen YJ , Cooper HS , Engstrom PF , Enzinger PC , Fenton MJ , Fuchs CS , Grem JL , Hunt S , Kamel A , Leong LA , Lin E , Messersmith W , Mulcahy MF , Murphy JD , Nurkin S , Rohren E , Ryan DP , Saltz L , Sharma S , Shibata D , Skibber JM , Sofocleous CT , Stoffel EM , Stotsky-Himelfarb E , Willett CG , Gregory KM , Freedman-Cass DA
Colon Cancer, Version 3.2014
Journal of the National Comprehensive Cancer Network. 2014 Jul;12(7) :1028-1059
PMID: WOS:000338901800010   
Back to previous list
Abstract
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.
Notes
Benson, Al B., III Venook, Alan P. Bekaii-Saab, Tanios Chan, Emily Chen, Yi-Jen Cooper, Harry S. Engstrom, Paul F. Enzinger, Peter C. Fenton, Moon J. Fuchs, Charles S. Grem, Jean L. Hunt, Steven Kamel, Ahmed Leong, Lucille A. Lin, Edward Messersmith, Wells Mulcahy, Mary F. Murphy, James D. Nurkin, Steven Rohren, Eric Ryan, David P. Saltz, Leonard Sharma, Sunil Shibata, David Skibber, John M. Sofocleous, Constantinos T. Stoffel, Elena M. Stotsky-Himelfarb, Eden Willett, Christopher G. Gregory, Kristina M. Freedman-Cass, Deborah A.